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This study reports on a microfluidic platform on which single multicellular spheroids from malignant
pleural mesothelioma (MPM), an aggressive tumor with poor prognosis, can be loaded, trapped and
tested for chemotherapeutic drug response. A new method to detect the spheroid viability cultured on
the microfluidic chip as a function of the drug concentration is presented. This approach is based on the
evaluation of the caspase activity in the supernatant sampled from the chip and tested using a microplate
reader. This simple and time-saving method does only require a minimum amount of manipulations
and was established for very low numbers of cells. This feature is particularly important in view of
personalised medicine applications for which the number of cells obtained from the patients is low. MPM
spheroids were continuously perfused for 48 hours with cisplatin, one of the standard chemotherapeutic
drugs used to treat MPM. The 50% growth inhibitory concentration of cisplatin in perfused MPM spheroids
was found to be twice as high as in spheroids cultured under static conditions. This chemoresistance
increase might be due to the continuous support of nutrients and oxygen to the perfused spheroids.1. Introduction
To further improve the effectiveness of cancer therapies, it is
widely believed that tumors should be considered in their three-
dimensional (3D) structure because cells can attain increased
resistance under those conditions.1 This phenomenon known
as multicellular resistance2 may not be fully reflected in two-
dimensional (2D) cell cultures.3 Therefore, 3D cell culture
models, such as spheroids, better reflect the in vivo behavior
of cells in tumor tissues and are excellent surrogates to predict
tumorigenic potential in vivo.4–6 Hence, multicellular spheroids
are becoming an important tool in cancer research by rep-
resenting a 3D system of intermediate cellular complexity
between monolayer cell cultures and in vivo tumors.2 How-
ever, spheroids cultured in standard well plates still do notfully reflect the in vivo conditions of the tumors, in particular
because in such a system, the spheroids are immerged in
a static solution of physiological medium rather than being
perfused, like in vivo vascularized tumors. Microfluidic plat-
forms that can easily mimic the geometrical shape and the
dynamic microenvironment of capillaries are ideally suited to
mimic this aspect. The greatest benefit of such perfused sys-
tems is the ability to preserve steady-state environments
where fresh medium and oxygen flow in and waste products
are removed, such as in the in vivo environment. Perfused
microfluidic systems also provide a more physiologically accu-
rate model of drug exposure and mass transport to cultured
cells.7–9 During the last decade, microfluidic technologies have
also demonstrated their ability to accurately manipulate cells
and tissues with unprecedented spatiotemporal precision.9,10
In parallel with ongoing developments in cellular and mole-
cular biology, these microfluidic systems are expected to signi-
ficantly contribute to the advancement of anti-cancer strategies
and are thought to represent the platform of choice for the
next-generation of in vitro cancer models.11
Although only just emerging, microfluidic platforms for
spheroid cultivation and anti-cancer drug testing have already
demonstrated great potential.12 These systems allow for the
growth of spheroids of homogeneous sizes and for the subse-
quent exposure to specific chemotherapeutical treatments. The
cytotoxic responses to drugs are mostly quantified using mor-
phology and fluorescent imaging13 or confocal microscopy.14–18
The latter technique is rather time-consuming, particularly foroyal Society of Chemistry 2014
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View Article Onlinespheroids, for which several cell layers must be analyzed. Cell
viability in spheroids is also demonstrated using scanning
electrochemical microscopy (SECM)19 as well as by evaluating the
fluorescence following conversion of alkoxyresorufin to resorufin.20
Recently, Kim and colleagues designed a cell viability assay on
chip derived from a standard 2D viability assay, particularly
the MTT ((3-4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium
bromide) assay.21 However, this rather complex microfluidic
system requires a number of valves allowing for successive and
precise microfluidic operations.
In this study, we propose a new microfluidic chemosensitive
platform for spheroid testing based on a simple and fast ana-
lysis system: the collection of the supernatant from the spheroid
cultured on chip and its further analysis using a standard
plate reader. In contrast to the time-demanding confocal
microscopy and the associated image analysis, this technique
is very fast and straightforward. We chose to assess apoptosis
in response to the chemotherapeutic insult based on the
caspase-3 activity collected in the spheroid supernatant. These
assays were performed using a limited number of spheroids
each made up of a small number of cells in the perspective of
personalized medicine applications.
As a proof of concept, malignant pleural mesothelioma
(MPM) cell lines were tested on this platform. MPM is a rare,
but highly aggressive and lethal, thoracic cancer with increasing
incidence throughout the world. This therapy-resistant neoplasm
is associated with exposure to asbestos in 60–70% of cases22,23
and is characterized by a locally aggressive growth pattern in
the lower parietal pleura with subsequent metastasis as the
disease progresses.24 The patients' survival time after surgery
averages 14 months.25 The standard chemotherapeutical approach
consists of a combination of cisplatin and pemetrexed. In this
study, the MPM spheroids are exposed to cisplatin and their
chemoresistances in a static and a dynamic environment are
compared. To the best of our knowledge, this is the first time
that the influence of perfusion on the chemoresistance of
spheroids is reported.2. Materials and methods
2.1. Spheroid formation and growth
All cell manipulations were performed in a sterile flow hood and
cells were incubated at 37 °C and 5% CO2 except if otherwise
stated. Cells, obtained from the human mesothelioma cell
line H2052 (ATCC-CRL-5915, ATCC, France), were maintained
in RPMI1640 (Invitrogen) media containing 10% fetal bovine
serum, FBS (Sigma) and 1% of a mixture of penicillin and
streptomycin (P–S, Invitrogen). Cells were passaged twice a
week using 0.25% trypsin with EDTA (Gibco) and counted
using Trypan blue staining and a hemocytometer (bright-line
Neubauer improved). Monolayer cell cultures were established
in 96-well plates with a density of 50 cells mm−2.
For spheroid formation, H2052 cells were seeded in a 24
ultra-low attachment flat-bottom well plate (Corning, Sigma)
at a density of 53 cells mm−2. Cells were maintained inThis journal is © The Royal Society of Chemistry 2014RPMI1640 media supplemented with 20 ng ml−1 of epidermal
growth factor, EGF (Gibco, Invitrogen), 20 ng ml−1 of basic
fibroblast growth factor, bFGF (Gibco, Invitrogen), 4 μg ml−1 of
insulin (BioReagent, Sigma), 2% serum-free supplement B27
(Gibco, Invitrogen) and 0.5% P–S. During the three days of
culture in media supplemented with growth factors, several
spheroids formed spontaneously. The spheroids, the sizes
of which varied between 50 and 400 μm, were filtered using a
40 μm nylon cell strainer (BD Falcon, Switzerland) to elimi-
nate single cells that did not spontaneously form spheroids.
All the filtered spheroids were trypsinized (TrypLE Express (1×),
LubioScience, Invitrogen) and incubated for 12 minutes to
disaggregate spheroids into single cells. The reason why the
spontaneously formed spheroids were not size sorted at 160 μm
is due to the small percentage (5–10%) of spheroids obtained
in this size. After stopping the reaction with RPMI1640 con-
taining 2% B27 and 0.5% P–S and four minute centrifugation
at 200 rcf, 200 cells (6 cells mm−2) were seeded in each well of a
non-tissue culture-treated 96 U-bottom well plate (BD Falcon) and
centrifuged at 515 rcf at room temperature (RT) for 10 minutes
(ref. 26) before being incubated for 48 hours.
2.2 Design and fabrication of the microfluidic platform
The spheroid trapping principle used on the microfluidic plat-
form is based on a serial entrapment for beads,27 which we
recently tested successfully on a device in which 500 μm in
diameter ovarian cancer spheroids17 were trapped and exposed
to chemotherapeutic drugs. The microfluidic chip comprises
two identical channels, each equipped with eight trapping
sections, each for one spheroid (Fig. 1A).
Briefly, the trapping principle works as follows: when the
chip is empty, the hydraulic resistance along the trapping
channel is lower than the hydraulic resistance of the bypass
channel. Thus, when a first spheroid is loaded on the chip, it
will follow the path of least resistance and will be kept in the
trapping section (Fig. 1B). The spheroid then acts as a plug,
increasing the hydraulic resistance of the trapping channel
and redirecting the main flow to the bypass channel (Fig. 1C).
The next spheroid loaded on the chip is trapped in the second
trapping section similar to the first one until all eight traps
are filled with spheroids.
Given the desired size of the spheroids to be tested on
chip, the hydraulic resistance (Rh) ratio between the trapping
section and the bypass channel is calculated using the
Hagen–Poiseuille equation Δp = RhQ, with:
R l
Dh h
  
128
4

 (1)
where μ is the dynamic viscosity of the physiological medium,
l the channel length, and Dh the hydraulic diameter of the
channel with a rectangular cross-section. The microfluidic
channels are designed so that the ratio between the flow
through the trapping channel (QT) and the flow through the
bypass channel (QB) is equal to 1.8. The hydraulic resistance
remains higher in the bypass channel when no spheroid is trapped.Lab Chip, 2014, 14, 1198–1205 | 1199
Fig. 1 A) A picture of the entire microfluidic system with 2 channels for spheroid testing (red for the chemotherapeutical drug treatment and
yellow for control). B) Schematic of the trapping principle: the first spheroid follows the fluidic path with the smallest fluidic resistance and falls in
the first trap. C) Once a spheroid is trapped, the flow resistance of the first trapping channel becomes larger than that of the bypass channel,
redirecting the flow with the second spheroid to the bypass channel until the next empty trap.
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View Article OnlineAll of the microchannels are 200 μm high and 200 μm wide,
except in the trapping channel. The latter is composed of
three different sections. The first consists of a spheroid trap
with a width of 200 μm and a length of 300 μm. The second
section is a 50 μm wide and 150 μm long narrow channel,
whereas the last part is a 500 μm × 500 μm × 200 μm channel with
two cuboids (100 μm × 100 μm × 200 μm) aligned horizontally
at the end of the channel to guide the spheroids along the
main channel. The two cuboids are spaced by 100 μm and are
located 100 μm from the border (Fig. 1B).
The devices were fabricated with poly(dimethylsiloxane)
(PDMS) (Sylgard 184, Dow Corning) using soft lithography
techniques. Briefly, a silicon mold made from a 4′′ silicon
wafer was microstructured with 200 μm deep microchannels
using deep reactive-ion etching (DRIE). Each silicon master
allowed simultaneous molding of seven PDMS devices. The
actual channel dimensions on the master were 205 ± 2 μm in
width and 205 ± 2 μm in depth. In the final step, the micro-
molded PDMS part was bonded to a microscopy glass slide
using oxygen plasma.2.3. Spheroid loading on the microfluidic platform
Prior to the spheroid loading, the microchannels were succes-
sively rinsed under sterile conditions with isopropanol, 70%
ethanol and deionized water. To prevent spheroid adherence
to the microchannels, a 100 μl solution of synperonic F-108
(1% w/v, Fluka, Sigma) was introduced in the chip and incu-
bated for 60 minutes. RPMI1640 containing 2% serum-free
supplement B27 and 0.5% P–S was then flashed twice into
the microchannels. The outlets of the chip were connected
under sterile conditions using Teflon tubes (ID = 0.6 mm) to
a 2 ml cryo vial (VWR International, Switzerland), allowing for
the collection of the supernatants. The loading of the spheroids
was performed using a 100 μl pipette tip containing eight
spheroids which was placed at the inlet. After trapping of the
spheroids, the two channels of the chip were connected to a
syringe pump (Harvard Apparatus) equipped with two 1 ml
syringes, and then perfused either with media or with media
containing cisplatin. Once trapped, the spheroids close the1200 | Lab Chip, 2014, 14, 1198–1205small trapping channels and are thus cultured in a diffusion
driven transport system.
Spheroids were perfused under sterile conditions at 37 °C
and 5% CO2 with a flow rate of 0.1 μl min
−1 for 48 hours.
The supernatant used for the cell viability test was sampled
during the whole assay period.
The spheroid loading on the chip (see video in the ESI†)
was observed using a small microscope placed in the incuba-
tor (JuLI smart fluorescent cell analyzer). The spheroid mor-
phology was visualized under perfusion every 10 minutes
using the same microscope.2.4. Chemosensitivity assays
Two methods were used for comparison purposes to assess the
50% growth inhibitory concentration (GI50) of cisplatin: the
XTT assay and the Caspase-Glo® 3/7 assay. The cell mortality
in monolayer cultures (2D) as well as in spheroids cultured
under static (3D) or perfused (3D on chip) conditions was assessed
using different concentrations of cisplatin (2 μM, 4 μM, 8 μM,
16 μM, 32 μM, 64 μM, 96 μM, 128 μM, 192 μM, 256 μM). For
this purpose, cisplatin (0.5 mg ml−1, Sandoz) was diluted in
either RPMI1640 media containing 10% FBS and 1% P–S for
2D cultures or RPMI1640 media containing 2% B27 and 0.5%
P–S for 3D cultures. The growth factors were removed from
the physiological medium used for the 3D cultures in order to
keep the spheroid size constant and avoid the presence of a
necrotic core. Staurosporine at a concentration of 1 μM was
used as the positive control. All experiments were done at
least in triplicate and over a time period of 48 hours.2.5. Analysis of apoptosis in multicellular spheroids
2.5.1 Immunostaining and fluorescence imaging: Hoechst/PI.
Hoechst/PI staining was performed on the spheroids to assess
their viability after the loading process. For the 3D cultures on
chip, 100 μl of Annexin-V-Fluos labelling solution with 1 μg ml−1
of Hoechst33342 was introduced in the chip and incubated
for 20 minutes. Then, fresh medium was flashed through the chip
to eliminate background signals from the staining. MicroscopicThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinepictures were taken using an inverted Leica DMI4000B fluorescent
microscope with a CCD camera (Leica DFC360 FX). The pictures
were processed using the Leica AF image analysis software and
further processed and visually analyzed using the Fiji image
analysis software based on ImageJ (http://rsbweb.nih.gov/ij/).
2.5.2 XTT assay. The XTT (Cell Proliferation Kit II, Roche) assay
was only performed for the monolayer cultures. 50 cells mm−2
were seeded in triplicate in a 96-well flat-bottom microplate
(BD Falcon) and incubated overnight to allow cell attachment.
After 48 hours of treatment with different concentrations of
cisplatin, the medium was aspirated and the cells replenished
with 100 μl of fresh medium and 50 μl of XTT labelling mixture.
After four hours of incubation, absorbance was measured at a
wavelength of 480 nm and a reference wavelength of 650 nm
using a multiwell plate reader (TECAN Infinite M1000).
2.5.3 Active caspase-3/7 assay. For the 2D cell cultures,
50 cells mm−2 were seeded in triplicate in a 48-well plate
(BD Falcon) and incubated overnight to allow cell attachment.
After 48 hours of treatment with different concentrations
of cisplatin, the supernatant was collected and mixed with
Caspase-Glo® 3/7 reagent (Promega) in a 1 : 1 ratio. After 3 hours
incubation at RT, luminescence was measured using a TECAN
Infinite M1000 reader.
For the 3D cell cultures, eight spheroids were seeded in
triplicate in a non-treated, flat-bottom 48-well plate and treated
for 48 hours with cisplatin. The Caspase-Glo® 3/7 assay was
directly added to each well in a 1 : 1 ratio. After 3 hours incuba-
tion at RT, luminescence was measured using a TECAN Infinite
M1000 reader.
For the perfused 3D cell culture system, eight spheroids were
loaded on the microfluidic device and perfused with cisplatin
for 48 hours with a flow rate of 0.1 μl min−1. Supernatants
were collected during the whole period of the experiments.
The analysis of the supernatants was performed identically as
for the supernatants of the 2D cell cultures described above.
2.6. Statistical analysis
Prism6 (GraphPad Software, Inc., Ja Jolla, CA) was used for
statistical analysis. The statistical significance was set at a
value of 0.05 or lower.Fig. 2 A) Distribution of the spheroid size obtained in the U-bottom
well plate (n = 126). B) Correlation between the spheroid size and the
number of cells per spheroid (n = 13).3. Results and discussion
MPM spheroids loaded on the microfluidic platform were
grown in non-adherent cultures in order to increase the proba-
bility to include tumor initiating cells (TIC) in the spheres.
TICs are known to present an increase chemoresistance and
are thought to be responsible for tumor recurrence,1 making
them a specific target of chemotherapeutical treatments. Spheroid
formation in non-adherent cultures has been used as a surrogate
in vitro method for detecting TIC from primary human tumors,
as recently reviewed by Valent et al.28 The presence of TICs
was also recently reported in cell lines,29 including H2052
MPM cells.30 Therefore, H2052 spheroids were first cultured
in an ultra-low attachment flat-bottom well plate,31 in whichThis journal is © The Royal Society of Chemistry 2014spheroids spontaneously formed. After the filtration of all single
cells the remaining spheroids with diameters varying between
50 and 400 μm were disaggregated and seeded in a 96 U-bottom
well plate where they formed spheroids with a size distribution
shown in Fig. 2A. The larger spheroids were then collected and
used for the experiments either on chip or in a standard well-plate.
The loading of the formed spheroids on chip, rather than creating
spheroids on chip from suspended cells, allowed a strict com-
parison between the static and the dynamic culture condi-
tions of the identically cultured spheroids.3.1. Spheroid growth
The spontaneous formation of the spheroids from the suspended
cells led to spheres, with a size distribution similar to a Gaussian
curve. The uniformity of the spheroid sizes was analyzed by
measuring a total of 126 spheroids after 3 days of culture
(Fig. 2A). Almost 36% of the spheroids had a size comprised
between 160 and 180 μm in diameter, 24% between 140 and
160 μm, 17% between 180 and 200 μm, 14% between 120 and
140 μm, 5.5% between 100 and 120 μm, and 4% were found toLab Chip, 2014, 14, 1198–1205 | 1201
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View Article Onlinehave a size comprised between 200 and 220 μm. The average
size of the obtained spheroids was found to be 161.1 ± 22.7 μm.
The number of cells per spheroid was counted in 13 trypsinized
spheroids (Fig. 2B). The number of cells of a 160 μm in diameter
spheroid used for the chemosensitivity assays was around 550
to 600 cells.3.2. Trapping and culture of spheroids on chip
The spheroids loaded on the chip were trapped using the dif-
ference in flow resistances between the trapping channel and
the bypass channel (see video in the ESI†). Once all eight
spheroids were trapped, they were perfused for 48 hours. As
illustrated in Fig. 3, the morphology of the spheroids stayed
unchanged during the whole perfusion period. It should be
mentioned that once the spheroids are trapped, the flow that
passes in the trapping section is negligible or even non-existent.
Therefore, the spheroids are not exposed to shear stress. In fact,
the delivery of the nutrients and of the oxygen contained in the
physiological medium is essentially due to diffusion from the
main channel to the trapped spheroids. This is obviously also
true in the other direction, for the cytokines and the cellular
waste products that are released by the spheroids.
The spheroids were then stained with Hoechst/PI to analyze
their cell viability in their dynamic environment and to prove
that spheroids did not develop a necrotic core, which is normally
established at sizes larger than 500 μm.1 The cell mortality
was found to be about 10% (data not shown), which coincides
with the normal cell mortality found in standard cell cultures.
Thus, one can conclude that this microfluidic environment
does not affect the cell viability.3.3 EdU proliferation assay
Cisplatin induces DNA intra- and inter-strand crosslinks, which
lead to the inhibition of DNA replication and, as a consequence,1202 | Lab Chip, 2014, 14, 1198–1205
Fig. 3 Bright field images of a spheroid trapped and perfused on chip
with control media. The images were taken at the beginning of the
perfusion as well as after 24, 36 and 48 hours of perfusion.to the death of the cells.32 Therefore, cisplatin affects primarily
proliferating cells and, to a lesser extent, arrested cells in the
G1 phase of the cell cycle. The proliferative activity of the
spheroids was therefore tested using a proliferation assay based
on 5-ethynyl-2′-deoxyuridine (EdU), a nucleotide analogue that
is incorporated during DNA replication. Our analysis revealed
that EdU incorporation was reduced from 44% to 13% in 3D
versus 2D culture under control conditions at the beginning of
the 48 hour treatment (Fig. 4). BrdU incorporation in human
lung cancer biopsies was reported to be about 10%,33 confirming
that the 3D model is more relevant for studying how cisplatin
affects the survival of cancer cells. Furthermore, the proliferative
activity is higher at the beginning of the 48 hour treatment
than after the treatment, even under control conditions. In
2D samples, the EdU incorporation decreases from 44 to 25%
and in 3D samples from 13 to 7%. This decrease indicates
that cells down-regulate their replication with the decrease of
nutrients to survive starvation for as long as possible and
therefore are more resistant to cisplatin treatment. Moreover,
the cell culture reaches confluence and therefore replication
is down-regulated. Surprisingly, we observed a 17% increase
of EdU incorporation in spheroids treated with 4 μM cisplatin
compared to spheroids under control conditions. This increase
may be explained by the activation of DNA repair mechanisms
and cell proliferation as a result of the cisplatin assault at low
concentration. This concentration is too low to kill the cells
but may be high enough to damage them by activating their
defense mechanisms. This includes cell proliferation and DNA
repair mechanisms.3.4. Chemosensitivity assays on chip
Cisplatin penetrates in the spheroids by diffusion and binds
with DNA to form inter- and intra-strand crosslinks. Cisplatin
is a small molecule that has been shown to diffuse in about
40 min in 280 μm spheroids.34 In our case, the spheroids are
smaller, meaning that the steady state is reached earlier and
that this time is negligible in comparison to the 48 h of perfusion.
The GI50 values for the 2D cultures were obtained using
the XTT assay and the caspase activity assay for comparison
purposes, whereas the GI50 of the 3D cultures were only tested
using the caspase activity assay.
3.4.1 XTT assay. The XTT assay, which is based on the
measurement of the activity of cellular enzymes that reduce
the tetrazolium dye, is one of the golden standards used to
assess cell viability. However, its use on chip is somewhat
complicated because it requires several manipulations.21 We
used it for the 2D model as a reference assay to validate the
caspase-3/7 assay that was used for the cell supernatant. The
GI50 of cisplatin for the 2D model (Fig. 5) was 11 μM after
48 hours of exposure. This result corresponds to the value
obtained by Cortes-Dericks et al.30 The effect of cisplatin on
the cells was further studied to discriminate the inhibition of
the cell growth from the cell death. Therefore, the metabolic
activity of cells in the control samples at day 0 (i.e. before starting
the treatment) was measured and used as the reference point.This journal is © The Royal Society of Chemistry 2014
Fig. 4 EdU incorporation in H2052 A) monolayer (n ≥ 8) and B) spheroid cultures (n ≥ 6). Data are presented as means ± SEM.
Fig. 5 The XTT assay in 2D cultures (n = 12). Measurements were
done at the beginning of the experiment (day 0) and at the end (day 2).
1 μM staurosporine was used as the negative control. Data are presented
as means ± SEM.
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View Article OnlineAs illustrated in Fig. 5, cell growth was inhibited in all samples
with a metabolic activity higher than this reference point, whereas
in the samples with a lower cellular metabolic activity, cisplatin
killed the cells. In this assay, the growth inhibition/cell death
limit for cisplatin was found to be 32 μM.
3.4.2 Caspase-3/7 assay. The caspase-3/7 activity appears
during the last steps of apoptotic cell death and was assessed
by the Caspase-Glo® 3/7 assay. This assay is very sensitive and
can be used even with a very small number of cells. The test was
first evaluated using the supernatant only and then compared
with samples containing spheroids. The caspase-3/7 activity was
found to be slightly lower in samples with the supernatant
compared to samples containing spheroids (Fig. 7 S1, ESI†).
However, both curves are comparable and give a similar GI50
response. The slight difference might indicate that a small
fraction of the caspase proteins remains in the spheroids and
is not collected in the supernatant. No GI50 values were reportedThis journal is © The Royal Society of Chemistry 2014so far to the best of our knowledge for H2052 spheroids exposed
to cisplatin. Although GI50 values are cell-type dependent, similar
values were obtained for non-small cell lung carcinoma cell
lines H460 and A549 exposed to cisplatin. In the 3D culture,
they were 84 μM (H460) and 75 μM (A549), whereas in the
2D culture, the IC50 values for these two cell lines were
around 4 μM.35
In addition, the GI50 for the 2D culture obtained using
the Caspase-Glo® 3/7 assay (20 μM) was similar to that using
the XTT test (14 μM) confirming the validity of the caspase
method. The Caspase-Glo® 3/7 assay was further used to charac-
terize the spheroid models. As expected, the chemoresistance of
the 3D model (54 μM) was found to be higher than that of the
2D model (20 μM) (Fig. 8 S2, ESI†).
However, the most interesting result was the two-fold
chemoresistance increase observed between the 3D and the
3D perfused model (Fig. 6). This increase might be due to the
enhanced and continuous support of nutrients and oxygen to
the perfused spheroids predicted by Hu et al. in a theoretical
model.36 It should be pointed out that the caspase-3/7 activity
under the 3D static conditions was measured directly in the wells
containing the spheroids and not only in the supernatant. This
prevented false positive results due to multipipetting steps.
Interestingly, the caspase-3/7 activity suddenly decreased above
a certain cisplatin concentration. This peak indicates the
highest level of apoptotic cells in the spheroids. Subsequently,
the caspase-3/7 activity decreased with the increase of the drug
concentration as a result of natural enzyme degradation and
cisplatin toxicity, which leads to cell necrosis instead of apoptosis
(private communication with Dr. Dan Lazar, Promega).
Table 1 summarizes the half-inhibitory concentrations obtained
for the three culture models. The XTT assay was used as the
golden standard in the 2D culture and confirmed the caspase-3/7
results. The Caspase-Glo® 3/7 assay reveals an increase of
chemoresistance between the 2D and the 3D cultures, although
the comparison between the 2D and 3D conditions is delicateLab Chip, 2014, 14, 1198–1205 | 1203
Fig. 6 The caspase-3/7 activity under 3D static (n = 3) and 3D
perfused (n = 3) conditions. Data are presented as means ± SEM.
Table 1 Summary table of GI50 of cisplatin (μM) for the three conditions
(2D, 3D and 3D perfused) obtained using two different viability assays
(XTT and Caspase-Glo® 3/7)
Culture condition XTT (μM) Caspase-3/7 (μM)
2D 11 20
3D — 54
3D perfused — 105
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
Ja
nu
ar
y 
20
14
. D
ow
nl
oa
de
d 
on
 0
8/
12
/2
01
4 
14
:5
5:
18
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinedue to the fact that cell density may influence the potency of
toxic compounds.374. Conclusions
The present microfluidic device allows the individual entrap-
ment of spheroids as well as their continuous perfusion. The
morphology of the perfused spheroids is not affected by
the dynamic environment and is similar to that of spheroids
cultured under static conditions. Chemotherapeutic tests were
performed on chip to evaluate the drug response of the per-
fused spheroids. A new technique, based on the collection and
the analysis off chip of the supernatant using a standard plate
reader, is demonstrated for the first time. The supernatant of
only 8 spheroids is analyzed for cell apoptosis based on the
Caspase-Glo® 3/7 assay. The use of a very small number of cells
(about 5000 per assay) is of utmost importance, in particular
for personalized medicine applications for which only a small
number of cells from the patients' own tumor are available.
Another advantage of this technique is clearly the very limited
number of manipulations required to sample the supernatant
and mix it with the Caspase-Glo® 3/7 reagent. In addition, the
use of the supernatant, rather than the cells themselves, makes
it possible to further investigate the spheroids using genomic
and proteomic analysis or even histologic assessments of the
spheroids. By perfusing the spheroids in this microfluidic system,
it can be shown that MPM spheroids treated with cisplatin,
one of the standard drugs used in the MPM therapy, were
more chemoresistant than those in a static environment. This
finding reveals the importance to better mimic the in vivo1204 | Lab Chip, 2014, 14, 1198–1205conditions found in MPM tumors, including the continuous
delivery of nutrients and oxygen.
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